Uncategorized
Candel reports prostate cancer drug’s long-term data ahead of FDA filing
Candel Therapeutics produced long-term follow-up data that may bolster the case for its prostate cancer drug that’s heading to the FDA for marketing approval later this year.
The company followed up with patients 20 months …